Stephanie Golob, Jaya Batra, Ersilia M DeFilippis, Matan Uriel, Matt Carey, Maureen Gaine, Angelo Mabasa, Justin Fried, Jayant Raikelkar, Susan Restaino, Sun Hi Lee, Farhana Latif, Melana Yuzefpolskaya, Paolo C Colombo, Jason Choe, David Majure, Douglas Jennings, Marcus R Pereira, Kevin Clerkin, Gabriel Sayer, Nir Uriel
Letermovir is a novel agent for the prevention of cytomegalovirus (CMV) infection and disease that, unlike traditional CMV DNA polymerase inhibitors, does not carry the risk of myelosuppression. The purpose of this study was to evaluate the safety, efficacy, and clinical application of letermovir for CMV prophylaxis in heart transplant (HT) recipients. Between November 1, 2019, and October 1, 2021, at a single, tertiary care hospital, 17 HT recipients were initiated on letermovir due to leukopenia while on valganciclovir...
December 2022: Clinical Transplantation